JBIO Stock — Jade Biosciences, Inc.

Jade Biosciences, Inc. (JBIO)

Updated October 16, 2026.

JBIO is a Stock. Its deepest 1-year drawdown was 50.1%.

Jade Biosciences is a biotechnology company developing therapies for inflammation and immunology indications in patients with autoimmune diseases, with its lead candidate JADE101 currently in phase 1 clinical trials and additional programs in preclinical development. The company does not currently distribute on a regular schedule; it has made special or one-time distributions, which may not recur. This security appeals to investors seeking exposure to early-stage biotechnology development rather than current income generation.

JBIO performance

Returns are updating. JBIO's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 50.1%.

JBIO key facts

Asset type

Stock

Asset class

Equity

Inception date

06/30/2021

Last close

$13.47 (as of 2026-10-16)

Market cap

$856,656,803

Average volume

981000.0

Dividend

$0.06857

Ex-dividend date

04/29/2025

Payout ratio

0.0%

EPS

$-1.92

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

JBIO risks and drawbacks

The deepest 1-year drawdown on record here is 50.1%.

More on JBIO

• All tickers starting with J

Tagged: Healthcare, Dividend.

Frequently asked questions